Diaceutics PLC Shareholding Update: Major Transaction by Key Stakeholder

Diaceutics ( (GB:DXRX) ) just unveiled an announcement.

Diaceutics PLC announced that Delia Keeling, closely associated with the company’s Chair, Peter Keeling, sold 500,000 ordinary shares at 126 pence each. This transaction reduces the Keelings’ combined shareholding to approximately 17.98% of the company’s issued share capital. This sale is significant as it reflects a change in the major holdings of the company, potentially impacting its market perception and shareholder dynamics.

The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.

More about Diaceutics

Diaceutics PLC is a prominent technology and solutions provider in the pharma and biotech industry. The company offers an end-to-end commercialization solution for precision medicines through its DXRX platform, which integrates data analytics, scientific, and advisory services. Diaceutics focuses on ensuring that patients receive the appropriate tests and therapies to improve their disease outcomes.

Average Trading Volume: 114,460

Technical Sentiment Signal: Buy

Current Market Cap: £114.1M

For detailed information about DXRX stock, go to TipRanks’ Stock Analysis page.